CA1142855A - Antitumoral composition and its process of preparation - Google Patents
Antitumoral composition and its process of preparationInfo
- Publication number
- CA1142855A CA1142855A CA000354516A CA354516A CA1142855A CA 1142855 A CA1142855 A CA 1142855A CA 000354516 A CA000354516 A CA 000354516A CA 354516 A CA354516 A CA 354516A CA 1142855 A CA1142855 A CA 1142855A
- Authority
- CA
- Canada
- Prior art keywords
- solution
- chlorhydrate
- ethanol
- amino
- boric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 6
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 4
- 238000000034 method Methods 0.000 title claims description 12
- 230000008569 process Effects 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title claims description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 14
- WXZGVQHBPNZQFD-UHFFFAOYSA-N ClO.NC1=CC=C(C(=O)C(C)(O)N(CC)CC)C=C1 Chemical compound ClO.NC1=CC=C(C(=O)C(C)(O)N(CC)CC)C=C1 WXZGVQHBPNZQFD-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000004327 boric acid Substances 0.000 claims abstract description 11
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 7
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 7
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 7
- 239000011780 sodium chloride Substances 0.000 claims abstract description 7
- 239000012153 distilled water Substances 0.000 claims abstract description 6
- 229940102223 injectable solution Drugs 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 18
- 238000011282 treatment Methods 0.000 description 11
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
- 229930003268 Vitamin C Natural products 0.000 description 6
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 6
- 229960004919 procaine Drugs 0.000 description 6
- 235000019154 vitamin C Nutrition 0.000 description 6
- 239000011718 vitamin C Substances 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 3
- 229910000085 borane Inorganic materials 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940063013 borate ion Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000003439 radiotherapeutic effect Effects 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- MROYOSVOQDJQDE-UHFFFAOYSA-N ClO.C(C)N(CC)C(C)O Chemical compound ClO.C(C)N(CC)C(C)O MROYOSVOQDJQDE-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- -1 borate ions Chemical class 0.000 description 1
- 125000005619 boric acid group Chemical group 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229940085991 phosphate ion Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RO97934 | 1979-06-23 | ||
| RO7997934A RO72294A2 (ro) | 1979-06-23 | 1979-06-23 | Produs medicamentos anticanceros si procedeu de preparare al acestuia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1142855A true CA1142855A (en) | 1983-03-15 |
Family
ID=20106169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000354516A Expired CA1142855A (en) | 1979-06-23 | 1980-06-20 | Antitumoral composition and its process of preparation |
Country Status (5)
| Country | Link |
|---|---|
| CA (1) | CA1142855A (enExample) |
| DE (1) | DE3023396C2 (enExample) |
| ES (1) | ES492468A0 (enExample) |
| FR (1) | FR2459659A1 (enExample) |
| RO (1) | RO72294A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0875246A1 (en) * | 1997-04-04 | 1998-11-04 | Showa Denko Kabushiki Kaisha | Pharmaceutical preparation of ascorbic acid derivatives for medical treatment of cancer |
| RO116524B1 (ro) * | 1999-05-26 | 2001-03-30 | M. Corneliu Niculescu | Produs farmaceutic antineoplazic, uman şi veterinar, procedeu de obţinere şi metodă de tratament antineoplazic |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2684323A (en) * | 1950-10-21 | 1954-07-20 | Physiological Chemicals Compan | Procaine ascorbate preparation |
| FR3385M (fr) * | 1963-12-02 | 1965-06-21 | Sobio Lab | Compositions thérapeutiques a base d'ascorbate de procaine. |
-
1979
- 1979-06-23 RO RO7997934A patent/RO72294A2/ro unknown
-
1980
- 1980-06-16 ES ES492468A patent/ES492468A0/es active Granted
- 1980-06-20 FR FR8013763A patent/FR2459659A1/fr active Granted
- 1980-06-20 CA CA000354516A patent/CA1142855A/en not_active Expired
- 1980-06-23 DE DE19803023396 patent/DE3023396C2/de not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| ES8104912A1 (es) | 1981-05-16 |
| DE3023396A1 (de) | 1981-01-22 |
| ES492468A0 (es) | 1981-05-16 |
| DE3023396C2 (de) | 1983-02-17 |
| FR2459659A1 (fr) | 1981-01-16 |
| FR2459659B1 (enExample) | 1983-05-27 |
| RO72294A2 (ro) | 1982-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Taylor et al. | Protamine is an inhibitor of angiogenesis | |
| Cascinu et al. | Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. | |
| JPH03169809A (ja) | 激痛状態の治療用医薬およびその医薬の製造方法 | |
| CN106692120A (zh) | 利多卡因的药物组合物及其用途 | |
| US6720011B1 (en) | Injectable composition for cancer treatment | |
| Brown et al. | The mechanism of acute ferrous sulphate poisoning | |
| CLASEN et al. | Steroid-antihistaminic therapy in experimental cerebral edema | |
| Volf | The effect of combinations of chelating agents on the translocation of intramuscularly deposited 239Pu nitrate in the rat | |
| CA1142855A (en) | Antitumoral composition and its process of preparation | |
| US2530480A (en) | Therapeutic preparations for intramuscular and subcutaneous injection and methods of making the same | |
| Cotter | Treatment of lead poisoning by chelation | |
| US9629931B2 (en) | Nanoparticles for the treatment of radiation skin injury | |
| RU2739746C9 (ru) | Фармацевтическое средство для лечения артрологических заболеваний | |
| Thompson et al. | Stimulation of local antibody formation in cornea by Grenz Rays | |
| RU2128975C1 (ru) | Глазные капли "баларпан" | |
| JPS5970615A (ja) | 口唇疱疹治療へのウンデシレン酸の使用 | |
| CN114423458A (zh) | 含有对二羟硼基苯丙氨酸的注射液剂 | |
| RU2832338C1 (ru) | Инъекционный раствор, содержащий п-боронофенилаланин | |
| JP3775813B2 (ja) | 病変異常組織治療用組成物，その製造方法およびその用途 | |
| Turner et al. | Diflunisal 500–750 mg versus aspirin 2600–3900 mg in the treatment of rheumatoid arthritis | |
| CN107773571A (zh) | 多种微量元素ⅳ药物组合物及其用途 | |
| WO2025221153A1 (en) | Treatment for hemangioma | |
| Gore et al. | Priming reduces the bone marrow toxicity of carboplatin | |
| KR20250070034A (ko) | 오렐라닌 제제 | |
| CN114929233A (zh) | V型磷酸二酯酶抑制剂组合物、制备它们的方法以及使用它们的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |